Tyson Bioresearch Incorporation operates within the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tyson Bioresearch Incorporation with three other
pharmaceutical manufacturers in Asia:
sales of 231.22 million Chinese Renmimbi [US$35.12 million]
of which 92%
was Reagent Income),
Eps Bio Technology Corp
(467.01 million Taiwanese Dollars [US$15.52 million]
OK Biotech Co Ltd
(1.04 billion Taiwanese Dollars [US$34.57 million]
of which 100%
was Ok Biotech Co Ltd).
During the year ended December of 2016, sales at
Tyson Bioresearch Incorporation were 281.09 million Taiwanese Dollars (US$9.34 million).
increase of 20.3%
versus 2015, when the company's sales were 233.74 million Taiwanese Dollars.
This was the third consecutive year of growth at Tyson Bioresearch Incorporation.